Abstract
Toxoplasmosis is a zoonotic protozoal disease caused by Toxoplasma gondii, an intracellular opportunistic protozoan parasite that can infect any warm-blooded vertebrate cell. In this study, zirconium, and iron-based metal-organic framework was prepared according to the solvothermal method. New nanocomposite (Curcumin@MOFs) was prepared by reacting curcumin with amino-functionalized metal-organic frameworks (Fe-MOF and UiO-66-NH2). Besides characterizations of the composite by powder X-ray diffraction and scanning electron microscope, nano-Curcumin@MOFs was used as a new novel structure as atrial for treatment of chronic toxoplasmosis. Results showed a reduced number of brain cysts, high levels of serum Toxo IgG, and normal histo-morphology with preserved parenchymal, and stromal tissues in rats groups treated with curcumin and Curcumin@MOFs nanocomposite.
Similar content being viewed by others
References
James SL. Metal-organic frameworks. Chem Soc Rev. 2003;32:276–88.
Furukawa H, Ko N, Go YB, Aratani N, Choi SB, Choi E, et al. Ultrahigh porosity in metal-organic frameworks. Science. 2010;329:424–8.
Lee J, Farha OK, Roberts J, Scheidt KA, Nguyen ST, Hupp JT. Metal–organic framework materials as catalysts. Chem Soc Rev. 2009;38:1450–9.
Rosi NL, Eckert J, Eddaoudi M, Vodak DT, Kim J, O’Keeffe M, et al. Hydrogen storage in microporous metal-organic frameworks. Science. 2003;300:1127–9.
Abdelhameed RM, Abdel-Gawad H, Taha M, Hegazi B. Separation of bioactive chamazulene from chamomile extract using metal-organic framework. J Pharm Biomed Anal. 2017;146:126–34.
Abdelhameed R, Abdel-Gawad H, Silva C, Rocha J, Hegazi B, Silva A. Kinetic and equilibrium studies on the removal of 14 C-ethion residues from wastewater by copper-based metal–organic framework. Int J Environm Sci Technol. 2018;15:2283–94.
Abdelhameed RM, Emam HE, Rocha J, Silva AM. Cu-BTC metal-organic framework natural fabric composites for fuel purification. Fuel Process Technol. 2017;159:306–12.
Abdelhameed RM, Ananias D, Silva AM, Rocha J. Building light‐emitting metal‐organic frameworks by post‐synthetic modification. ChemSelect. 2017;2:136–9.
Abdelhameed RM, Carlos LD, Silva AM, Rocha J. Engineering lanthanide-optical centres in IRMOF-3 by post-synthetic modification. New J Chem. 2015;39:4249–58.
Abdelhameed RM, Carlos LD, Rabu P, Santos SM, Silva AM, Rocha J. Designing near‐infrared and visible light emitters by postsynthetic modification of Ln+ 3–IRMOF‐3. Eur J Inorganic Chem. 2014;2014:5285–95.
Horcajada P, Chalati T, Serre C, Gillet B, Sebrie C, Baati T, et al. Porous metal–organic-framework nanoscale carriers as a potential platform for drug delivery and imaging. Nat Mater. 2010;9:172.
Abazari R, Mahjoub AR, Ataei F, Morsali A, Carpenter-Warren CL, Mehdizadeh K, et al. Chitosan immobilization on bio-MOF nanostructures: a biocompatible pH-responsive nanocarrier for doxorubicin release on MCF-7 cell lines of human breast cancer. Inorganic Chem. 2018;57:13364–79.
Chowdhuri AR, Singh T, Ghosh SK, Sahu SK. Carbon dots embedded magnetic nanoparticles@ chitosan@ metal organic framework as a nanoprobe for pH sensitive targeted anticancer drug delivery. ACS Appl Mater Interfaces. 2016;8:16573–83.
Neufeld MJ, Lutzke A, Tapia JB, Reynolds MM. Metal–organic framework/chitosan hybrid materials promote nitric oxide release from S-nitrosoglutathione in aqueous solution. ACS Appl Mater Interfaces. 2017;9:5139–48.
Eissa MM, Barakat AM, Amer EI, Younis LK. Could miltefosine be used as a therapy for toxoplasmosis? Exp Parasitology. 2015;157:12–22.
Lang C, Groß U, Lüder CG. Subversion of innate and adaptive immune responses by Toxoplasma gondii. Parasitology Res. 2007;100:191–203.
Remington JS, Thulliez P, Montoya JG. Recent developments for diagnosis of toxoplasmosis. J Clinical Microbiology. 2004;42:941–5.
Kim K, Weiss LM. Toxoplasma gondii: the model apicomplexan. Int J Parasitol. 2004;34:423–32.
Goldstein EJ, Montoya JG, Remington JS. Management of toxoplasma gondii infection during pregnancy. Clin Infect Dis. 2008;47:554–66.
Kur J, Holec-Gąsior L, Hiszczyńska-Sawicka E. Current status of toxoplasmosis vaccine development. Expert Rev Vaccines. 2009;8:791–808.
McLeod R, Khan AR, Noble GA, Latkany P, Jalbrzikowski J, Boyer K, et al. Severe sulfadiazine hypersensitivity in a child with reactivated congenital toxoplasmic chorioretinitis. Pediatric Infect Dis J. 2006;25:270–2.
Değerli K, Kilimcioğlu AA, Kurt Ö, Tamay AT, Özbilgin A. Efficacy of azithromycin in a murine toxoplasmosis model, employing a Toxoplasma gondii strain from Turkey. Acta Tropica. 2003;88:45–50.
Schmidt DR, Hogh B, Andersen O, Hansen SH, Dalhoff K, Petersen E. Treatment of infants with congenital toxoplasmosis: tolerability and plasma concentrations of sulfadiazine and pyrimethamine. Eur J Pediatrics. 2006;165:19–25.
McFadden D, Boothroyd J. Cytochrome b mutation identified in a decoquinate-resistant mutant of toxoplasma gondii. J Eukaryotic Microbiol. 1999;46:81S.
McFadden DC, Tomavo S, Berry EA, Boothroyd JC. Characterization of cytochrome b from Toxoplasma gondii and Qo domain mutations as a mechanism of atovaquone-resistance. Mol Biochem Parasitol. 2000;108:1–12.
Aspinall TV, Joynson DH, Guy E, Hyde JE, Sims PF. The molecular basis of sulfonamide resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosis. J Infect Dis. 2002;185:1637–43.
Lai B-S, Witola WH, El Bissati K, Zhou Y, Mui E, Fomovska A. et al. Molecular target validation, antimicrobial delivery, and potential treatment of Toxoplasma gondii infections. Proc Natl Acad Sci. 2012;109:14182–7.
Mathew A, Fukuda T, Nagaoka Y, Hasumura T, Morimoto H, Yoshida Y, et al. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer’s disease. PLoS ONE. 2012;7:e32616.
Gressler L, Oliveira C, Coradini K, Dalla Rosa L, Grando T, Baldissera M, et al. Trypanocidal activity of free and nanoencapsulated curcumin on Trypanosoma evansi. Parasitology. 2015;142:439–48.
Flora G, Gupta D, Tiwari A. Nanocurcumin: a promising therapeutic advancement over native curcumin. Crit Rev Ther Drug Carrier Syst. 2013;30:331–68.
Wang S, Su R, Nie S, Sun M, Zhang J, Wu D, et al. Application of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals. J Nutr Biochem. 2014;25:363–76.
Ghosh A, Banerjee T, Bhandary S, Surolia A. Formulation of nanotized curcumin and demonstration of its antimalarial efficacy. Int J Nanomed. 2014;9:5373.
Djurkoviae-Djakoviae O, Milenkoviae V. Murine model of drug-induced reactivation of toxoplasma gondii. Acta Protozool. 2001;40:99–106.
Suvarna KS, Layton C, Bancroft JD. Bancroft’s Theory and Practice of Histological Techniques E-Book: Elsevier Health Sciences; 2018.
Duncan DB. Multiple range tests for correlated and heteroscedastic means. Biometrics. 1957;13:164–76.
Shaikh J, Ankola D, Beniwal V, Singh D, Kumar MR. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci. 2009;37:223–30.
Abdelhameed RM, Rehan M, Emam HE. Figuration of Zr-based MOF@ cotton fabric composite for potential kidney application. Carbohydrate Polym. 2018;195:460–7.
Abdelhameed RM, Abdelhameed RE, Kamel HA. Iron-based metal-organic-frameworks as fertilizers for hydroponically grown Phaseolus vulgaris. Mater Lett. 2019;237:72–9.
Ward RJ, Crichton RR, Taylor DL, Della Corte L, Srai SK, Dexter DT. Iron and the immune system. J Neural Transmission. 2011;118:315–28.
Feng J, Ma W, Xu Z, Wang Y, Liu J. Effects of iron glycine chelate on growth, haematological and immunological characteristics in weanling pigs. Animal Feed Sci Technol. 2007;134:261–72.
Huo C, Xiao J, Xiao K, Zou S, Wang M, Qi P, et al. Pre-treatment with zirconia nanoparticles reduces inflammation induced by the pathogenic H5N1 influenza virus. Int J Nanomed. 2020;15:661.
Hassabo AA, Mousa AM, Abdel-Gawad H, Selim MH, Abdelhameed RM. Immobilization of l-methioninase on a zirconium-based metal–organic framework as an anticancer agent. J Mater Chem B. 2019;7:3268–78.
Emam HE, Darwesh OM, Abdelhameed RM. In-growth metal organic framework/synthetic hybrids as antimicrobial fabrics and its toxicity. Colloids Surf B Biointerfaces. 2018;165:219–28.
Simanjuntak TP, Hatta M, Tahir AM, Sirait RH, Karo MB, Tambaib T, et al. Analysis of anti-toxoplasma immunoglobulin G and immunoglobulin M antibody levels after intervention with Curcuma Longa extract on early pregnant mice with acute toxoplasmosis. J Global Infect Dis. 2019;11:25.
Hegazi AG, Al Guthami FM, Al Gethami AF, Barakat AM. Egyptian propolis 12: influence of Propolis on Cytokines of Toxoplasma gondii Infected Rats. Int J Curr Microbiol App Sci. 2017;6:202–11.
Basniwal RK, Buttar HS, Jain V, Jain N. Curcumin nanoparticles: preparation, characterization, and antimicrobial study. J Agric Food Chem. 2011;59:2056–61.
Dandekar PP, Jain R, Patil S, Dhumal R, Tiwari D, Sharma S, et al. Curcumin-loaded hydrogel nanoparticles: application in anti-malarial therapy and toxicological evaluation. J Pharm Sci. 2010;99:4992–5010.
Kelly MN, Kolls JK, Happel K, Schwartzman JD, Schwarzenberger P, Combe C, et al. Interleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection. Infection Immunity. 2005;73:617–21.
Rasmussen HB, Christensen SB, Kvist LP, Karazmi A. A simple and efficient separation of the curcumins, the antiprotozoal constituents of Curcuma longa. Planta Med. 2000;66:396–8.
Reddy RC, Vatsala PG, Keshamouni VG, Padmanaban G, Rangarajan PN. Curcumin for malaria therapy. Biochem Biophys Res Commun. 2005;326:472–4.
Cui L, Miao J, Cui L. Cytotoxic effect of curcumin on malaria parasite Plasmodium falciparum: inhibition of histone acetylation and generation of reactive oxygen species. Antimicrobial Agents Chemotherapy. 2007;51:488–94.
Akhtar F, Rizvi MMA, Kar SK. Oral delivery of curcumin bound to chitosan nanoparticles cured Plasmodium yoelii infected mice. Biotechnol Adv. 2012;30:310–20.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
El-Shafey, A.A.M., Hegab, M.H.A., Seliem, M.M.E. et al. Curcumin@metal organic frameworks nano-composite for treatment of chronic toxoplasmosis. J Mater Sci: Mater Med 31, 90 (2020). https://doi.org/10.1007/s10856-020-06429-y
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s10856-020-06429-y